Skip to main content
. 2023 Feb 28;11(3):731. doi: 10.3390/biomedicines11030731

Figure 2.

Figure 2

Metformin improves the prognosis of CRCLM patients. The survival analysis shows five-year overall survival rate of CRCLM patients with (a) RHGP, (b) DHGP, or (c) mixed tumours in the presence or absence of metformin usage. (d) The difference in five-year overall survival between cohorts treated with and without metformin among all CRCLM patients. Kaplan–Meier analysis with log-rank tests was used to analyze the survival curves and statistical significance.